摘要
目的:探讨雄激素受体(AR)在浸润性乳腺癌中的表达及与临床病理特征的关系.方法:采用回顾性队列研究,纳入2022年1月至2024年12月莆田学院附属医院收治的浸润性乳腺癌患者150例,根据病案系统收集患者临床资料,分析评估AR表达与雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体-2(HER-2)、Ki-67增殖指数及肿瘤生物学特性的相关性.结果:150例浸润性乳腺癌患者AR阳性率为70.67%,表达与患者年龄、绝经状态及TNM分期未呈显著关联性(P＞0.05);与组织学分级、ER/PR状态、HER-2表达及Ki-67增殖指数存在显著相关性(P＜0.05).结论:AR表达在不同组织学分级等特征中表现出差异性,也提示AR表达可能为浸润性乳腺癌患者病情评估和治疗决策提供参考依据.
Abstract
Objective:To investigate the expression level of androgen receptor(AR)in invasive breast cancer and its relationship with clinicopathological features.Methods:A retrospective cohort study was conducted,including 150 patients with invasive breast cancer admitted to the Affiliated Hospital of Putian University from January 2022 to December 2024.Clinical data were collected from the medical record system,and the correlation between AR expression levels and estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor-2(HER-2),Ki-67 proliferation index,and tumor biological characteristics was analyzed and evaluated.Results:The AR-positive rate in the 150 invasive breast cancer patients was 70.67%.Its expression level showed no significant correlation with age,menopausal status,or TNM stage(P>0.05),but was significantly correlated with histological grade,ER/PR status,HER-2 expression,and Ki-67 proliferation index(P<0.05).Conclusion:The expression level of AR varies across different histological grades and other characteristics,suggesting that AR expression may serve as a reference for disease assessment and treatment decision-making in patients with invasive breast cancer.
NETL
NSTL
万方数据